Evidence map›Paper›PMID 26706109›Full record

ReviewExperimental cell research2016

On the evolution of the pulmonary alveolar lipofibroblast.

John S Torday, Virender K Rehan

Open access · bronzeAbstract readReview
In one paragraph

Review in Experimental cell research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Alveologenesis: What Governs Secondary Septa Formation.International journal of molecular sciences · 2021
    Review
  9. Review
  10. Review
  11. Article
  12. Shared and distinct mechanisms of fibrosis.Nature reviews. Rheumatology · 2019
    Review
  13. Article
  14. Vascular Niche in Lung Alveolar Development, Homeostasis, and Regeneration.Frontiers in bioengineering and biotechnology · 2019
    Review
  15. Review
  16. Article
  17. Review
  18. [Research advances in association between pediatric obesity and bronchial asthma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

John S TordayDepartment of Pediatrics, Harbor-UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502-2006, USA. Electronic address: jtorday@labiomed.org.
Virender K RehanDepartment of Pediatrics, Harbor-UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502-2006, USA. Electronic address: vrehan@labiomed.org.
Harbor–UCLA Medical Center · USUCLA Medical Center · US

Funding

HORMONAL REGULATION OF LUNG DEVELOPMENT;PTHrP BIOLOGYR01HL055268 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI TORDAY, JOHN STEVEN · 1997 to 2009
$3.3M
Developmental Nicotine Exposure & Transgenerationally Altered Lung PhenotypeR01HL127237 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2016 to 2019
$1.8M
PPARgamma Signaling/Lung Fibroblast TransdifferentiationR01HL075405 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2005 to 2009
$1.7M
Fibroblast Cell Signaling in Utero Nicotine-Induced Lung InjuryR01HD051857 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2008 to 2012
$1.7M
Molecular Basis of Childhood Asthma Following Perinatal Vitamin D DeficiencyR21HL107118 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2011 to 2012
$377k
In Utero Nicotine Exposure & Transgenerational Transmission of AsthmaR21HD071731 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2012 to 2013
$369k
A Molecular Approach to Prevent Pulmonary Dysfunction in the Intrauterine GrowthR03HD058948 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2009 to 2010
$137k
NHLBI NIH HHS HL055268NHLBI NIH HHS HL075405NHLBI NIH HHS HL107118NHLBI NIH HHS R01 HL055268NHLBI NIH HHS R01 HL075405NHLBI NIH HHS R01 HL127237NHLBI NIH HHS R21 HL107118NICHD NIH HHS HD058948NICHD NIH HHS HD071731NICHD NIH HHS HD51857NICHD NIH HHS R01 HD051857NICHD NIH HHS R03 HD058948NICHD NIH HHS R21 HD071731
6 · The paper itself

Abstract

The pulmonary alveolar lipofibroblast was first reported in 1970. Since then its development, structure, function and molecular characteristics have been determined. Its capacity to actively absorb, store and 'traffic' neutral lipid for protection of the alveolus against oxidant injury, and for the active supply of substrate for lung surfactant phospholipid production have offered the opportunity to identify a number of specialized functions of these strategically placed cells. Namely, Parathyroid Hormone-related Protein (PTHrP) signaling, expression of Adipocyte Differentiation Related Protein, leptin, peroxisome proliferator activator receptor gamma, and the prostaglandin E2 receptor EP2- which are all stretch-regulated, explaining how and why surfactant production is 'on-demand' in service to ventilation-perfusion matching. Because of the central role of the lipofibroblast in vertebrate lung physiologic evolution, it is a Rosetta Stone for understanding how and why the lung evolved in adaptation to terrestrial life, beginning with the duplication of the PTHrP Receptor some 300 mya. Moreover, such detailed knowledge of the workings of the lipofibroblast have provided insight to the etiology and effective treatment of Bronchopulmonary Dysplasia based on physiologic principles rather than on pharmacology.

Indexed as

AnimalsCell DifferentiationFibroblastsHumansLungPulmonary AlveoliReceptor, Parathyroid Hormone, Type 1Signal TransductionReceptor, Parathyroid Hormone, Type 1ADRPCell–Cell interactionsFibroblastNeutral lipid traffickingPPARγPTHrP

Identifiers

PMID26706109
PMCPMC4744566
OpenAlexW2200965179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.